The DOI matches its Crossref record; 138 of the 141 references it cites were found in a registry or an index.
Gut microbiome interactions with drug metabolism, efficacy, and toxicity
Open accessAbstract
The gut microbiota has both direct and indirect effects on drug and xenobiotic metabolisms, and this can have consequences for both efficacy and toxicity. Indeed, microbiome-driven drug metabolism is essential for the activation of certain prodrugs, for example, azo drugs such as prontosil and neoprontosil resulting in the release of sulfanilamide. In addition to providing a major source of reductive metabolizing capability, the gut microbiota provides a suite of additional reactions including acetylation, deacylation, decarboxylation, dehydroxylation, demethylation, dehalogenation, and importantly, in the context of certain types of drug-related toxicity, conjugates hydrolysis reactions. In addition to direct effects, the gut microbiota can affect drug metabolism and toxicity indirectly via, for example, the modulation of host drug metabolism and disposition and competition of bacterial-derived metabolites for xenobiotic metabolism pathways. Also, of course, the therapeutic drugs themselves can have effects, both intended and unwanted, which can impact the health and composition of the gut microbiota with unforeseen consequences.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The gut microbiota can have both direct and indirect effects on the metabolism of drugs, with consequences for both efficacy and toxicity.60, 61”
From Emerging issues in probiotic safety: 2023 perspectives (2023) · cites this paper as [60]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Host-gut microbiota metabolic interactions
Nicholson, J. K., Holmes, E., Kinross, J., Burcelin, R., Gibson, G., Jia, W., & Pettersson, S. (2012) · Science · doi:10.1126/science.1223813 · Cited by 4,760
Self-citationDethlefsen, L., & Relman, D. A. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1000087107 · Cited by 2,421
Molecular Analysis of Commensal Host-Microbial Relationships in the Intestine
Hooper, L. V., Wong, M. H., Thelin, A., Hansson, L., Falk, P. G., & Gordon, J. I. (2001) · Science · doi:10.1126/science.291.5505.881 · Cited by 2,202
Proton pump inhibitors affect the gut microbiome
Imhann, F., Bonder, M. J., Vich Vila, A., Fu, J., Mujagic, Z., Vork, L., Tigchelaar, E. F., Jankipersadsing, S. A., Cenit, M. C., Harmsen, H. J. M., et al. (2016) · Gut · doi:10.1136/gutjnl-2015-310376 · Cited by 1,371
Understanding 'Global' Systems Biology: Metabonomics and the Continuum of Metabolism
Nicholson, J. K., & Wilson, I. D. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1157 · Cited by 1,126
Self-citationAlleviating Cancer Drug Toxicity by Inhibiting a Bacterial Enzyme
Wallace, B. D., Wang, H., Lane, K. T., Scott, J. E., Orans, J., Koo, J. S., Venkatesh, M., Jobin, C., Yeh, L.-A., Mani, S., et al. (2010) · Science · doi:10.1126/science.1191175 · Cited by 1,080
Long-term impacts of antibiotic exposure on the human intestinal microbiota
Jernberg, C., Löfmark, S., Edlund, C., & Jansson, J. K. (2010) · Microbiology · doi:10.1099/mic.0.040618-0 · Cited by 1,067
Venkatesh, M., Mukherjee, S., Wang, H., Li, H., Sun, K., Benechet, A. P., Qiu, Z., Maher, L., Redinbo, M. R., Phillips, R. S., et al. (2014) · Immunity · doi:10.1016/j.immuni.2014.06.014 · Cited by 1,066
Self-citationGut microorganisms, mammalian metabolism and personalized health care
Nicholson, J. K., Holmes, E., & Wilson, I. D. (2005) · Nature Reviews Microbiology · doi:10.1038/nrmicro1152 · Cited by 945
Self-citationProton pump inhibitors alter the composition of the gut microbiota
Jackson, M. A., Goodrich, J. K., Maxan, M.-E., Freedberg, D. E., Abrams, J. A., Poole, A. C., Sutter, J. L., Welter, D., Ley, R. E., Bell, J. T., et al. (2016) · Gut · doi:10.1136/gutjnl-2015-310861 · Cited by 895
Flagged first, then by citations
3 of the 141 references couldn’t be matched to a known paper.
Research works printed but not linked: 1
- Peppercorn, 1976, Drug-bacteria interaction, Rev Drug Metab Drug Interact, 11, 75
Cited by
Sorted by citations
Items 101–104 of 104
Murakami, T., Bodor, E., & Bodor, N. (2023) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2023.2203857 · Cited by 41
Aklillu, E., Carrillo, J. A., Makonnen, E., Bertilsson, L., & Djordjevic, N. (2018) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-018-2448-y · Cited by 28
Jourová, L., Anzenbacher, P., Lišková, B., Matušková, Z., Hermanová, P., Hudcovic, T., Kozáková, H., Hrnčířová, L., & Anzenbacherová, E. (2017) · Folia Microbiologica · doi:10.1007/s12223-017-0517-8 · Cited by 26
Disposition and Absolute Bioavailability of Orally Administered Orforglipron in Healthy Participants
Morse, B. L., Bhattachar, S., Ma, X., Coutant, D. E., Czeskis, B., Nicoll, C., & Cassidy, K. C. (2026) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.1594 · Cited by 7
Metadata
- Authors
- Wilson, I. D., & Nicholson, J. K.
- Affiliations
- Imperial College London (GB)
- Corresponding author
- Wilson, Ian D.
- Venue
- Translational Research
- Publisher
- Elsevier BV
- Published
- 2017-01
- Volume
- 179
- Pages
- 204-222
- ISSN
- 1878-1810 (ISSN-L)
- 1931-5244
- PMC
- PMC5718288
- OpenAlex
- W2517182458
- Cited by
- 656
- References
- 141
- Citations by year
- 2026: 81 · 2025: 74 · 2024: 66 · 2023: 71 · 2022: 70 · 2021: 91 · 2020: 75 · 2019: 63 · 2018: 42 · 2017: 20
- FWCI
- 7.48
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Translational research (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Spiral (Imperial College London) (submittedVersion, cc-by-nc-nd)
- Funders
- Wellcome Trust (104933)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Keywords
- gut microbiota, drug metabolism, xenobiotic metabolism, drug efficacy, drug toxicity, prodrug activation, sulfanilamide, Prontosil, reductive metabolism, conjugate hydrolysis, bacterial metabolites
- MeSH terms
- Gastrointestinal Microbiome, Bacteria, Pharmaceutical Preparations, Humans, Xenobiotics, Treatment Outcome, Drug-Related Side Effects and Adverse Reactions
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
